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Many brain diseases (such as meningitis, encephalitis,
multiple sclerosis (MS), stroke, brain tumors, epilepsy,
Alzheimer's disease, AIDS related dementia, Parkinson's
disease) are under treated or cannot be treated at all due
to the presence of the barriers in the brain (blood-brain
barrier, blood-cerebrospinal fluid barrier and the brain-
cerebrospinal fluid barrier). The blood-brain barrier is fac-
ing the blood side and is the largest barrier for transport
of macromolecular drugs from blood to brain. Therefore,
targeting strategies to the BBB are necessary to selectively
and specifically transport macromolecular drugs to the
brain. This can be accomplished by exploiting receptor-
mediated transport (RMT) systems at the blood-brain bar-
rier. Moreover, enhanced selectivity can be obtained by
targeting transport systems induced during disease condi-
tions. Macromolecular protein drugs can be directly
linked to a carrier molecule that fits to a RMT system.
However, such applications often result in decreased
activity of the resulting (fusion) protein and are prone to
induce activation of and subsequent degradation by the
immune system. Therefore, liposomal systems coated
with carrier molecules are an alternative to deliver macro-
molecular protein drugs to the brain by targeting them to
the blood-brain barrier.
A second, alternative approach may be to target genes to
the brain. However, in our opinion it will be very difficult
to transport such genes across the BBB. Our approach is to
use the blood-brain barrier as a "protein factory" follow-
ing delivery of genes encoding therapeutic proteins to the
blood-brain barrier. Such proteins can be excreted by the
blood-brain barrier endothelial cells to subsequently per-
form their therapeutic action in the brain. Genes can be
attached to poly-cationic polymers like poly-ethylene-
imines or incorporated into liposomal systems and tar-
geted to the brain by a carrier molecule that fits to a RMT
system.
For this purpose we use a human applicable carrier pro-
tein known as CRM197. CRM197 is the non-toxic mutant
of diphtheria toxin that uses the membrane-bound pre-
cursor of heparin-binding epidermal growth factor (HB-
EGF) as its transport receptor [1]. Membrane bound HB-
EGF is constitutively expressed on the blood-brain barrier
Moreover, HB-EGF expression is strongly up-regulated on
cerebral blood vessels in diseases with inflammatory
events like Alzheimer's disease, Parkinson's disease, MS,
stroke/ischemia, tumors, epilepsy and encephalitis. This
may provide disease induced drug targeting to the brain.
Research so far has shown in vitro proof of principle for
the transport of biopharmaceuticals across the BBB [2-4].
Therefore, this brain drug delivery technology holds out a
great promise for future therapeutic applications.
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